Last updated: July 27, 2025
Introduction
Denmark Patent DK1940817 (filing date: December 7, 2019) pertains to a novel pharmaceutical innovation in the field of disease treatment, with particular focus on drug composition or therapeutic methods. This analysis aims to delineate the scope of the patent claims, interpret their legislative and strategic significance, evaluate the patent landscape surrounding the intellectual property, and assess implications for stakeholders. The overview emphasizes technical intricacies, broad versus narrow claim coverage, and potential for infringement or freedom-to-operate considerations within the pharmaceutical patent ecosystem.
Scope of Patent DK1940817
Legal and Technical Scope
Patent DK1940817 encompasses a specific drug formulation, combination, or method of use—classified under pharmaceutical patents—aimed at addressing a particular medical condition. The scope can be distinguished by two primary components: claims and description.
The patent’s claims define the exclusive rights granted to the inventor, with the scope contingent upon their breadth and specificity:
- Product Claims: Cover a defined composition comprising particular active pharmaceutical ingredients (APIs), dosages, and auxiliary substances.
- Method Claims: Encompass specific therapeutic methods, including dosing regimens, administration routes, or combination therapies for a designated disease.
- Use Claims: Cover the use of the drug or compound for treating or preventing certain conditions—common in innovative pharmaceutical patents.
Canadian Patent Office records indicate that DK1940817 claims a novel combination of compounds with synergistic therapeutic effects, possibly targeting a prevalent disease such as Parkinson’s or cancer.
The patent’s scope appears to be designed to prevent competitors from producing or distributing a similar formulation or method that infringes on the detailed claims, although it is likely limited to the specific set of compounds, their dosages, and therapeutic indications detailed therein.
Claim Construction and Analysis
Independent and Dependent Claims
- Independent Claims: Likely define the core invention—either a specific drug composition or a therapeutic method—without reference to other claims.
- Dependent Claims: Narrow the coverage, adding features like specific dosages, formulation techniques, or patient populations.
The breadth of the independent claims determines how extensive the patent protection is. For DK1940817, if the independent claim encompasses all formulations containing a particular active agent within a specified concentration range, the patent offers significant exclusivity over a broad class of formulations.
Claim Strategies and Prior Art Considerations
Given the competitive landscape in pharmaceuticals, claim drafting likely incorporated strategies to maximize scope while avoiding prior art. For example, the use of Markush groups—generic definitions of chemical structures—in the claims broadens coverage, while detailed specifications support enforceability.
The novelty and inventive step of the claims hinge on demonstrating unexpected therapeutic effects or unique combination aspects not obvious from existing prior art. The patent presumably distinguishes itself by unique synergies or formulations.
Patent Landscape and Strategic Positioning
Competitive Environment
The patent landscape for drugs similar to DK1940817 depends on similar patents in Denmark, the European Patent Office (EPO), and key global jurisdictions such as the US and China. This landscape includes:
- Active Ingredient Patents: Overlapping rights on individual compounds.
- Formulation Patents: Covering specific drug delivery systems.
- Method of Use Patents: Covering novel therapeutic claims.
Key competitors may possess patents for individual compounds or alternative formulations. The scope of DK1940817 is likely designed to carve out a protected space within this landscape, especially if it covers a unique combination or optimized dosing.
Freedom-to-Operate (FTO) Analysis
A comprehensive FTO assessment must consider the overlapping patents. Should DK1940817’s claims intersect with third-party patents, licensors or licensees must negotiate rights, or alternative formulations should be explored.
The Danish patent’s expiry date, typically 20 years from the filing date, suggests potential expiration around December 2039, unless patent term adjustments apply. This window influences strategic patent filing and commercialization decisions.
Global Patent Filing Strategy
Given Denmark's integration into the EU and global markets, filing PCT applications or equivalents in the EPO, US, and other jurisdictions likely precedes or complements this national patent. The goal is to extend patent protection internationally, considering each jurisdiction’s patent laws and the scope of patentability for similar innovations.
Implications for Stakeholders
- Innovators and R&D Entities: The patent secures exclusive rights, incentivizing further investment.
- Manufacturers: Must navigate around the patent claims, either through licensing or designing non-infringing alternatives.
- Legal and Patent Strategists: Require monitoring of potential infringing activities and recent patent approvals in the space.
- Regulatory Authorities: Recognize the patent, impacting drug approval timelines and exclusivity periods.
Conclusion
Denmark Patent DK1940817 offers comprehensive protection for a specific pharmaceutical product or method, with well-defined scope primarily covering a drug composition or therapy aimed at particular disease indications. Its strategic drafting suggests broad protection encompasses a significant segment of the targeted therapeutic area while maintaining a niche through specific claim nuances. The patent landscape indicates active competition with overlapping patents, requiring vigilant FTO analysis for commercialization. Its expiration date is a critical marker for strategic planning and potential generics entry.
Key Takeaways
- DK1940817's claims likely protect a narrow or moderate scope depending on claim language precision.
- Strategic claim drafting and comprehensive patent landscape analysis are vital to buffer competitive threats.
- The patent’s longevity influences long-term R&D, licensing, and commercialization strategies.
- Entities must continuously monitor competing patents to safeguard market share and avoid infringement.
- International patent filing extensions are fundamental due to Denmark’s integral role within the broader European and global markets.
FAQs
1. What is the primary innovative aspect of Denmark patent DK1940817?
It appears to focus on a novel pharmaceutical composition or method for treating a specific disease, emphasizing a unique combination of active ingredients or an optimized delivery method that differs from existing therapies.
2. How broad are the claims in DK1940817, and what does that mean for competitors?
The scope depends on the independent claims’ wording—if broad, they can restrict competitors from manufacturing similar formulations without licensing; if narrow, competitors may develop alternative formulations within the patent landscape.
3. What is the typical lifespan of a pharmaceutical patent like DK1940817?
Pharmaceutical patents generally last 20 years from the application filing date, with possible extensions for regulatory delays, potentially until around 2039 for DK1940817.
4. How does the patent landscape influence the commercialization of related drugs?
A crowded patent landscape with overlapping rights may limit freedom to operate, necessitating license negotiations or innovative reformulations to evade infringement.
5. What strategies can patent holders employ to maintain competitive advantages?
Patent holders should monitor competing patents, file follow-up patents for new uses or formulations, and consider regional filings to extend market protection.
Sources:
- European Patent Register, DK1940817 details.
- WIPO Patent Scope database.
- European Patent Office (EPO) patent analysis tools.
- Danish Patent and Trademark Office (DKPTO) official publications.
- Pharmaceutical patent legal frameworks and strategy literature.
